Unnamed: 0,title,date,stock,sentiment
967890.0,Otonomy And AGTC To Present Preclinical Results Supporting Selection Of Product Candidate For GJB2 Gene Therapy Hearing Loss Program,2020-05-12 08:06:00-04:00,OTIC,positive
967891.0,"Otonomy Q4 EPS $(0.360) Beats $(0.440) Estimate, Sales $93.000K Beat $50.000K Estimate",2020-05-07 08:16:00-04:00,OTIC,neutral
967892.0,96 Biggest Movers From Yesterday,2020-04-28 04:22:00-04:00,OTIC,neutral
967893.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,OTIC,neutral
967894.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,OTIC,neutral
967895.0,Otonomy Q4 EPS $(0.36) Beats $(0.44) Estimate,2020-02-27 16:37:00-05:00,OTIC,neutral
967896.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,OTIC,positive
967897.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,OTIC,neutral
967898.0,94 Biggest Movers From Yesterday,2020-02-12 05:13:00-05:00,OTIC,neutral
967899.0,"Otonomy Offers Preclinical Results For GJB2 Gene Therapy Collaboration, Cisplatin Otoprotection Program",2020-01-28 07:33:00-05:00,OTIC,neutral
967900.0,"Otonomy 8-K Includes Press Release With Corporate, Product Pipeline Update",2020-01-09 07:29:00-05:00,OTIC,neutral
967901.0,"The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger",2020-01-03 07:55:00-05:00,OTIC,negative
967902.0,"The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe",2020-01-02 08:46:00-05:00,OTIC,negative
967903.0,38 Stocks Moving In Tuesday's Mid-Day Session,2019-12-31 12:18:00-05:00,OTIC,neutral
967904.0,"Mid-Morning Market Update: Markets Mostly Flat; Seadrill Reports 3-Year, $199M Middle East Contract",2019-12-31 10:20:00-05:00,OTIC,neutral
967905.0,55 Biggest Movers From Yesterday,2019-12-31 04:21:00-05:00,OTIC,neutral
967906.0,32 Stocks Moving In Monday's Mid-Day Session,2019-12-30 12:13:00-05:00,OTIC,neutral
967907.0,58 Biggest Movers From Friday,2019-12-30 04:51:00-05:00,OTIC,neutral
967908.0,51 Biggest Movers From Tuesday,2019-12-26 05:14:00-05:00,OTIC,neutral
967909.0,33 Stocks Moving In Tuesday's Mid-Day Session,2019-12-24 11:34:00-05:00,OTIC,neutral
967910.0,"Benzinga's Top Upgrades, Downgrades For December 24, 2019",2019-12-24 10:49:00-05:00,OTIC,positive
967911.0,20 Stocks Moving in Tuesday's Pre-Market Session,2019-12-24 08:05:00-05:00,OTIC,neutral
967912.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,OTIC,negative
967913.0,"Oppenheimer Initiates Coverage On Otonomy with Outperform Rating, Announces $8 Price Target",2019-12-24 06:15:00-05:00,OTIC,neutral
967914.0,"Otonomy Q3 EPS $(0.33) Beats $(0.45) Estimate, Sales $125K Miss $210K Estimate",2019-11-05 16:30:00-05:00,OTIC,negative
967915.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,OTIC,negative
967916.0,AGTC And Otonomy Announce Strategic Collaboration To Develop And Commercialize Gene Therapy For Congenital Hearing Loss,2019-10-01 07:32:00-04:00,OTIC,negative
967917.0,58 Biggest Movers From Yesterday,2019-10-01 05:56:00-04:00,OTIC,neutral
967918.0,Otonomy Reports Initiation Of Phase 1/2 Trial Of OTO-413 In Hearing Loss,2019-09-17 07:30:00-04:00,OTIC,negative
967919.0,"Benzinga's Top Upgrades, Downgrades For August 29, 2019",2019-08-29 09:38:00-04:00,OTIC,positive
967920.0,23 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-08-29 08:40:00-04:00,OTIC,neutral
967921.0,"H.C. Wainwright Initiates Coverage On Otonomy with Buy Rating, Announces $8 Price Target",2019-08-29 07:41:00-04:00,OTIC,neutral
967922.0,Otonomy Filing Shows Registration For $40M Common Stock Offering,2019-08-01 17:00:00-04:00,OTIC,neutral
967923.0,"Otonomy Q2 EPS $(0.38) Beats $(0.48) Estimate, Sales $190K Miss $250K Estimate",2019-08-01 17:00:00-04:00,OTIC,negative
967924.0,"Otonomy Q1 EPS $(0.39) Beats $(0.43) Estimate, Sales $192K Miss $320K Estimate",2019-05-06 17:38:00-04:00,OTIC,negative
967925.0,Otonomy Announces OTIPRIO Co-Promotion Agreement With Glenmark Therapeutics For Acute Otitis Externa Indication,2019-05-02 07:58:00-04:00,OTIC,positive
967926.0,Otonomy Initiates Phase 1/2 Clinical Trial Of OTO-313 In Tinnitus,2019-04-11 07:34:00-04:00,OTIC,neutral
967927.0,"The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings",2019-03-05 07:24:00-05:00,OTIC,positive
967928.0,"Otonomy Q4 EPS $(0.42) Beats $(0.48) Estimate, Sales $208K Beat $110K Estimate",2019-03-04 16:19:00-05:00,OTIC,neutral
967929.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-03-03 09:41:00-05:00,OTIC,neutral
967930.0,"Otonomy Offers Corporate, Product Pipeline Update",2019-01-03 07:37:00-05:00,OTIC,neutral
967931.0,"The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO",2018-12-28 07:29:00-05:00,OTIC,neutral
967932.0,"The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede",2018-12-27 07:51:00-05:00,OTIC,neutral
967933.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,OTIC,neutral
967934.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,OTIC,positive
967935.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,OTIC,positive
967936.0,"Cantor Fitzgerald Initiates Coverage On Otonomy with Overweight Rating, Announces $9 Price Target",2018-11-15 07:54:00-05:00,OTIC,negative
967937.0,"Otonomy Q3 EPS $(0.41) Beats $(0.47) Estimate, Sales $113K Beat $100K Estimate",2018-11-05 16:13:00-05:00,OTIC,neutral
967938.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,OTIC,neutral
967939.0,"The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program",2018-10-12 07:34:00-04:00,OTIC,negative
967940.0,"Stocks Which Set New 52-Week Low Yesterday, September 12th",2018-09-13 10:19:00-04:00,OTIC,negative
967941.0,"Stocks Which Set New 52-Week Low Yesterday, September 11th",2018-09-12 15:29:00-04:00,OTIC,negative
967942.0,"The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt",2018-09-12 08:26:00-04:00,OTIC,positive
967943.0,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",2018-09-11 08:25:00-04:00,OTIC,negative
967944.0,Otonomy Inc. S-3 Shows Filing For Up To $150M Mixed Shelf Offering,2018-09-10 17:06:00-04:00,OTIC,neutral
967945.0,38 Biggest Movers From Yesterday,2018-08-28 04:38:00-04:00,OTIC,neutral
967946.0,Otonomy Q2 EPS $(0.44) Misses $(0.38) Estimate,2018-08-08 16:23:00-04:00,OTIC,negative
967947.0,52 Biggest Movers From Yesterday,2018-08-07 05:19:00-04:00,OTIC,neutral
967948.0,Otonomy Announces A Co-Promotion Agreement with Mission Pharma for Acute Otitis Externa Indication,2018-08-06 07:40:00-04:00,OTIC,positive
967949.0,Otonomy Begins Phase 3 Clinical Trial of OTIVIDEX in Ménière's Disease,2018-07-26 07:35:00-04:00,OTIC,neutral
967950.0,"Otonomy Q1 EPS $(0.37) Misses $(0.35) Estimate, Sales $301K Beat $100K Estimate",2018-05-09 16:21:00-04:00,OTIC,negative
967951.0,42 Biggest Movers From Yesterday,2018-03-20 04:48:00-04:00,OTIC,neutral
967952.0,31 Stocks Moving In Monday's Mid-Day Session,2018-03-19 12:49:00-04:00,OTIC,neutral
967953.0,"Eeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In Portfolio Rebalancing",2018-03-19 12:45:00-04:00,OTIC,neutral
967954.0,Shares Of Otonomy Down 7.9% After Earlier Downgrade From J.P. Morgan,2018-03-19 11:24:00-04:00,OTIC,positive
967955.0,JP Morgan Downgrades Otonomy to Underweight,2018-03-19 08:57:00-04:00,OTIC,positive
967956.0,25 Stocks Moving In Monday's Pre-Market Session,2018-03-12 08:04:00-04:00,OTIC,neutral
967957.0,44 Biggest Movers From Friday,2018-03-12 04:59:00-04:00,OTIC,neutral
967958.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-11 16:58:00-04:00,OTIC,neutral
967959.0,36 Stocks Moving In Friday's Mid-Day Session,2018-03-09 12:41:00-05:00,OTIC,neutral
967960.0,"Otonomy Reports Q4 EPS $(0.62) vs $(0.60) Est., Sales $270K vs $460K",2018-03-08 16:26:00-05:00,OTIC,neutral
967961.0,"Shares Of Otonomy Resume Trade, Now Up 8% At $6.15/Share",2018-03-02 12:16:00-05:00,OTIC,positive
967962.0,Otonomy To Resume Trade At 12:15 p.m.,2018-03-02 12:13:00-05:00,OTIC,neutral
967963.0,Otonomy to Resume Trading at 12:15 PM ET,2018-03-02 12:00:00-05:00,OTIC,neutral
967964.0,Otonomy Announces FDA Approval of Otirprio,2018-03-02 11:59:00-05:00,OTIC,positive
967965.0,Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates,2018-02-28 10:08:00-05:00,OTIC,neutral
967966.0,26 Stocks Moving In Friday's Mid-Day Session,2017-12-29 12:36:00-05:00,OTIC,neutral
967967.0,Otonomy Option Alert: Jan 19 $5 Calls at the Bid: 1000 @ $0.7 vs 2249 OI; Ref=$5.025,2017-12-19 14:28:00-05:00,OTIC,positive
967968.0,30 Stocks Moving In Tuesday's Pre-Market Session,2017-11-28 08:08:00-05:00,OTIC,neutral
967969.0,UPDATE: Otonomy Says Discussions Are Underway To Divest OTIPRIO,2017-11-27 16:34:00-05:00,OTIC,neutral
967970.0,"UPDATE: Otonomy Says Will Discontinue Commercial Support Of OTIPRIO, Expected To Save $20M+ In '18",2017-11-27 16:33:00-05:00,OTIC,positive
967971.0,Otonomy Reports Co. Will Focus Resources On Completing OTIVIDEX Development To Support US Regulatory Approval For Meniere's Disease,2017-11-27 16:33:00-05:00,OTIC,positive
967972.0,Otonomy Option Alert: Dec 15 $7.5 Calls at the Bid: 1001 @ $0.35 vs 6001 OI; Ref=$4.7,2017-11-10 09:36:00-05:00,OTIC,positive
967973.0,51 Biggest Movers From Yesterday,2017-11-10 05:30:00-05:00,OTIC,neutral
967974.0,Mid-Afternoon Market Update: Dow Falls Over 200 Points; Otonomy Shares Spike Higher,2017-11-09 14:31:00-05:00,OTIC,positive
967975.0,40 Stocks Moving In Thursday's Mid-Day Session,2017-11-09 12:32:00-05:00,OTIC,neutral
967976.0,Mid-Day Market Update: magicJack Surges On Acquisition News; Meet Group Shares Decline,2017-11-09 12:02:00-05:00,OTIC,positive
967977.0,Otonomy Rips 90% After Meniere's Disease Drug Achieves Primary Endpoint,2017-11-09 10:51:00-05:00,OTIC,neutral
967978.0,Mid-Morning Market Update: Markets Open Lower; Macy's Profit Tops Estimates,2017-11-09 10:12:00-05:00,OTIC,positive
967979.0,30 Stocks Moving In Thursday's Pre-Market Session,2017-11-09 08:14:00-05:00,OTIC,neutral
967980.0,"Otonomy Reports Q3 EPS $(0.69) vs. $(0.76) Est., Sales $282K vs. $330K Est.",2017-11-08 16:58:00-05:00,OTIC,neutral
967981.0,Otonomy Shares Spike as High as $7.20 after-hours as Co Reports VERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's Disease Met Primary Endpoint,2017-11-08 16:27:00-05:00,OTIC,positive
967982.0,"Adam Feuerstein Tweets: Trying again:

Best performers in Q3: $DMTX $MRNS $MYOK

Worst: $OTIC $AXON $ICPT",2017-09-29 16:24:00-04:00,OTIC,neutral
967983.0,Otonomy Says Cost Cutting Efforts Will Save $7M in 2017,2017-09-13 07:32:00-04:00,OTIC,positive
967984.0,"Otonomy to Cut its Non-Commercial Workforce by 1/3, Says Has Enough Cash to Last Into 2020",2017-09-13 07:31:00-04:00,OTIC,negative
967985.0,20 Stocks Moving In Friday's Pre-Market Session,2017-09-01 08:02:00-04:00,OTIC,neutral
967986.0,18 Biggest Mid-Day Gainers For Thursday,2017-08-31 12:28:00-04:00,OTIC,neutral
967987.0,The Market In 5 Minutes,2017-08-31 09:35:00-04:00,OTIC,neutral
967988.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-08-31 08:09:00-04:00,OTIC,neutral
967989.0,Mid-Afternoon Market Update: NASDAQ Rises Over 1%; Dycom Industries Shares Slide,2017-08-30 14:32:00-04:00,OTIC,positive
967990.0,12 Biggest Mid-Day Losers For Wednesday,2017-08-30 12:56:00-04:00,OTIC,negative
967991.0,Mid-Day Market Update: AeroVironment Jumps After Strong Q1 Results; Otonomy Shares Plummet,2017-08-30 12:10:00-04:00,OTIC,positive
967992.0,JP Morgan Downgrades Otonomy to Neutral,2017-08-30 10:16:00-04:00,OTIC,positive
967993.0,Mid-Morning Market Update: Markets Mostly Higher; Analog Devices Profit Tops Expectations,2017-08-30 10:10:00-04:00,OTIC,positive
967994.0,Here's The News That Sent Otonomy Shares Crashing,2017-08-30 09:24:00-04:00,OTIC,positive
967995.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-08-30 08:13:00-04:00,OTIC,neutral
967996.0,"Otonomy Shares Resume Trade, Now Down 75%",2017-08-30 07:32:00-04:00,OTIC,positive
967997.0,Otonomy Shares To Resume Trade At 7:30 a.m. EDT,2017-08-30 07:10:00-04:00,OTIC,positive
967998.0,UPDATE: Otonomy Says 'is undertaking a review of its product pipeline plans and commercial efforts in order to identify opportunities to extend its cash runway and build shareholder value',2017-08-30 07:04:00-04:00,OTIC,positive
967999.0,UPDATE: Otonomy Says Will Immediately Suspend All Development Activities For OTIVIDEX,2017-08-30 07:03:00-04:00,OTIC,negative
968000.0,"Otonomy Offers Results From AVERTS-1 Phase 3 Trial For OTIVIDEX In Patients With Meniere's Disease: Missed Primary Endpoint, All Key Vertigo Secondary Endpoints",2017-08-30 07:03:00-04:00,OTIC,negative
968001.0,Otonomy Shares Halted News Pending,2017-08-30 06:57:00-04:00,OTIC,positive
968002.0,15 Biggest Mid-Day Gainers For Tuesday,2017-08-15 12:57:00-04:00,OTIC,neutral
968003.0,JP Morgan Upgrades Otonomy to Overweight,2017-08-15 07:13:00-04:00,OTIC,neutral
968004.0,"Otonomy Reports Q2 Loss/Share $(0.77) vs. $(0.82) Est., Sales $326K vs. $330K Est.",2017-08-03 16:47:00-04:00,OTIC,neutral
968005.0,"Otonomy Announces FDA Acceptance of OTIPRIO Supplemental NDA, Announces March 2, 2018 PDUFA Date",2017-07-18 07:39:00-04:00,OTIC,positive
968007.0,Otonomy Reports Successful End-of-Phase 2 Review by FDA for OTIPRIO,2017-06-22 07:30:00-04:00,OTIC,positive
968008.0,"Otonomy Reports Q1 EPS $(0.89) vs $(0.86) Est., Sales $358K vs $240K Est.",2017-05-04 16:40:00-04:00,OTIC,neutral
968009.0,Otonomy Reports Q4 EPS $(0.88) vs. $(0.93) Est.,2017-03-02 16:21:00-05:00,OTIC,neutral
968010.0,Otonomy Begins Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss,2017-01-19 07:31:00-05:00,OTIC,negative
968011.0,Otonomy Gives Pipeline Update,2017-01-09 07:35:00-05:00,OTIC,neutral
968012.0,15 Biggest Mid-Day Gainers For Thursday,2017-01-05 12:38:00-05:00,OTIC,neutral
968013.0,Otonomy Announces 'Positive' Top-Line Results from Phase 3 Clinical Trial of OTIPRIO,2017-01-05 07:05:00-05:00,OTIC,neutral
968014.0,Otonomy Names Dr. Kathie Bishop Chief Scientific Officer,2016-11-30 07:31:00-05:00,OTIC,neutral
968015.0,Otonomy Reports Q3 EPS $(0.91) vs. Est. $(0.95),2016-11-03 16:14:00-04:00,OTIC,neutral
968016.0,Otonomy Holding An Investor Day Today,2016-10-07 08:25:00-04:00,OTIC,neutral
968017.0,"Otonomy Reports Q2 Loss -$0.98 vs Est Loss/Share -$0.90, Sales $76K",2016-08-04 17:54:00-04:00,OTIC,negative
968018.0,Otonomy Initiates Patient Enrollment in Single Phase 3 Clinical Trial of OTIPRIO in Patients with Acute Otitis Externa,2016-06-09 07:32:00-04:00,OTIC,neutral
968019.0,WallachBeth Initiates Coverage on Otonomy at Buy,2016-05-26 10:45:00-04:00,OTIC,neutral
968020.0,10 Biggest Mid-Day Market Gainers,2016-05-13 12:37:00-04:00,OTIC,neutral
968021.0,"Otonomy Reports Phase 3 Clinical Trial Plan For OTIPRIO Based On Successful Phase 2 FDA Review, Expects To Submit sNDA To FDA First Half of 2017",2016-04-18 07:31:00-04:00,OTIC,positive
968022.0,Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière's Disease,2016-03-23 07:30:00-04:00,OTIC,neutral
968023.0,Otonomy Announces Publication of OTIPRIO Phase 3 Clinical Trial Results in JAMA Otolaryngology,2016-03-18 07:31:00-04:00,OTIC,neutral
968024.0,Otonomy Reports Q4 Adj EPS $(0.77) Vs Est $(0.95),2016-03-07 16:21:00-05:00,OTIC,neutral
968025.0,Otonomy Begins Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes,2016-03-03 07:31:00-05:00,OTIC,neutral
968026.0,Otonomy Reports Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss,2016-01-26 07:08:00-05:00,OTIC,positive
968027.0,Here's Why There's Been A Rush Of Biotech Offerings,2016-01-07 11:32:00-05:00,OTIC,neutral
968028.0,Otonomy Announces Prices 5M Share Offering @$20.00/Share,2016-01-07 04:16:00-05:00,OTIC,positive
968029.0,Mid-Afternoon Market Update: Dow Slides Over 300 Points; Otonomy Shares Tumble Following Public Offering Of Stock,2016-01-06 14:57:00-05:00,OTIC,positive
968030.0,Mid-Day Market Update: Crude Oil Falls Over 4%; Conatus Pharmaceuticals Shares Rise Following Positive Results In Phase 2 Study,2016-01-06 12:14:00-05:00,OTIC,positive
968031.0,Mid-Morning Market Update: Markets Open Lower; Monsanto Posts Narrower-Than-Expected Loss,2016-01-06 10:07:00-05:00,OTIC,negative
968032.0,Benzinga's Top #PreMarket Losers,2016-01-06 08:22:00-05:00,OTIC,negative
968033.0,Shares Of Otonomy Plunge Following Public Offering Of Stock,2016-01-06 08:14:00-05:00,OTIC,positive
968034.0,Notable Buy-Side Biotech Analyst Brad Loncar Notes Heavy Biotech Offerings Taking Place After Hours In Tweet,2016-01-05 16:15:00-05:00,OTIC,neutral
968035.0,Otonomy Announces Proposed Public Offering of ~$100M Common Stock,2016-01-05 16:01:00-05:00,OTIC,neutral
968036.0,Otonomy To Resume Trading at 8am,2015-12-11 07:35:00-05:00,OTIC,neutral
968037.0,Otonomy Cuts Rev. Operating Expense Guidance From $70-$75M To $65-$70M,2015-12-11 07:33:00-05:00,OTIC,negative
968038.0,Otontomy Reports FDA Approval Of OTIPRIO For Pediatric Placements On Tympanostomy Tube Placement Surgery,2015-12-11 07:32:00-05:00,OTIC,positive
968039.0,"Otonomy Halted, News Pending",2015-12-11 07:25:00-05:00,OTIC,neutral
968040.0,Otonomy Completes Enrollment in OTIPRIO(TM) Phase 2 Trial and Demonstrates Clinical Feasibility in Patients With Acute Otitis Externa,2015-12-01 07:00:00-05:00,OTIC,neutral
968041.0,Otonomy Reports Initiation of Patient Enrollment in US Phase 3 Trial of OTO-104 in Meniere's Disease,2015-11-18 07:01:00-05:00,OTIC,neutral
968042.0,Otonomy Reports Q3 EPS $(0.66) vs. Est. $(0.83),2015-11-10 16:22:00-05:00,OTIC,neutral
968043.0,"Otonomy Holds Investor, Analyst Day and Provides Corporate Update",2015-10-07 08:06:00-04:00,OTIC,neutral
968044.0,"Otonomy Given FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311",2015-10-05 07:31:00-04:00,OTIC,neutral
968045.0,Otonomy to Present Results for AuriPro(TM) Phase 3 and OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting,2015-09-24 07:32:00-04:00,OTIC,neutral
968046.0,Otonomy Reports Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere's Disease,2015-09-09 07:31:00-04:00,OTIC,positive
968047.0,Otonomy Reports $300M Mixed Shelf Offering Through S-3 Filing,2015-09-03 16:18:00-04:00,OTIC,neutral
968048.0,Otonomy Appoints Ted Schroeder to Board of Directors,2015-09-01 07:31:00-04:00,OTIC,neutral
968049.0,Bernstein Upgrades Otonomy to Outperform,2015-08-10 09:51:00-04:00,OTIC,neutral
968050.0,Otonomy Begins Phase 2 Clinical Trial for AuriPro in Second Label Expansion Indication,2015-07-28 07:31:00-04:00,OTIC,neutral
968051.0,"Otonomy, Renren And Other Names To Watch Heading Into Next Week",2015-05-23 14:32:00-04:00,OTIC,neutral
968052.0,Morning Market Losers,2015-05-22 09:55:00-04:00,OTIC,negative
968053.0,"JP Morgan Downgrades Otonomy to Neutral, Lowers PT to $30.00",2015-05-22 05:50:00-04:00,OTIC,positive
968054.0,"BlackBerry, Monro Muffler, Valeant In Thursday's After-Hours Movers",2015-05-21 18:47:00-04:00,OTIC,neutral
968055.0,Otonomy Appoints Eric Loumeau as General Counsel and COO,2015-05-21 16:05:00-04:00,OTIC,neutral
968056.0,"Otonomy Shares Halted, News Pending",2015-05-21 16:03:00-04:00,OTIC,positive
968057.0,Otonomy Reports Q1 Loss of $0.52/Share vs Loss of $0.53/Share Est.,2015-05-12 16:18:00-04:00,OTIC,negative
968058.0,Otonomy Reports FDA Acceptance of New Drug Application For AuriPro,2015-04-28 07:06:00-04:00,OTIC,positive
968059.0,Otonomy Presents AuriPro Phase 3 Results at American Society of Pediatric Otolaryngology Conference,2015-04-27 07:32:00-04:00,OTIC,neutral
968060.0,Otonomy to Show AuriPro Phase 3 Data at American Society of Pediatric Otolaryngology Conference,2015-04-21 07:33:00-04:00,OTIC,neutral
968061.0,Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere's Disease Patients,2015-04-20 07:33:00-04:00,OTIC,positive
968062.0,16 Biotech Catalysts SunTrust Is Tracking,2015-04-06 19:38:00-04:00,OTIC,neutral
968063.0,Otonomy Starts Phase 2 Clinical Trial for AuriPro in Label Expansion Indication,2015-03-26 07:31:00-04:00,OTIC,neutral
968064.0,Otonomy Reports Q4 EPS -$0.46 Vs Est -$0.64,2015-03-18 16:16:00-04:00,OTIC,neutral
968065.0,Benzinga's Top Initiations,2015-02-04 09:25:00-05:00,OTIC,positive
968066.0,Cowen Initiates Otonomy At Outperform,2015-02-04 08:32:00-05:00,OTIC,neutral
968067.0,"Cowen & Company Initiates Coverage on Otonomy at Outperform, Announces $55.00 PT",2015-02-04 05:33:00-05:00,OTIC,neutral
968068.0,Benzinga's Top #PreMarket Losers,2015-01-23 08:23:00-05:00,OTIC,negative
968069.0,Otonomy Prices 2.55M Share Offering @$29.25/Share,2015-01-22 20:42:00-05:00,OTIC,positive
968070.0,Otonomy Launches $75M Follow-on Public Offering,2015-01-21 16:04:00-05:00,OTIC,neutral
968071.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,2015-01-12 11:03:00-05:00,OTIC,neutral
968072.0,Otonomy Files Registration Statement for $75M Proposed Follow-on Public Offering,2015-01-08 17:30:00-05:00,OTIC,neutral
968073.0,Otonomy Announces $86.3M Offering,2015-01-08 17:30:00-05:00,OTIC,neutral
968074.0,"Bernstein Downgrades Otonomy to Market Perform, Maintains $29.00 PT",2014-12-17 06:07:00-05:00,OTIC,neutral
968075.0,Otonomy Achieves Patient Enrollment Target In Phase 2b Clinical Trial Of OTO-104 In Meniere's Disease,2014-12-01 07:03:00-05:00,OTIC,neutral
968076.0,Otonomy Obtains Rights to Gacyclidine Data from Ipsen for Development of OTO-311 as Tinnitus Treatment,2014-11-06 05:12:00-05:00,OTIC,neutral
968077.0,Otonomy Appoints Anthony Yost as Chief Commercial Officer,2014-10-21 07:30:00-04:00,OTIC,neutral
968078.0,Otonomy Enrolls First Meniere's Disease Patients In OTO-104 Multiple-Dose Safety Study,2014-10-09 07:32:00-04:00,OTIC,positive
968079.0,"Midday Gainers From September 19 - Alibaba Group Holding Ltd, Concur Technologies, Inc. And More",2014-09-19 14:13:00-04:00,OTIC,neutral
968080.0,"TPG Group Holdings Advisors Buys 171,875 Shares of Otonomy @$16.00/Share -Form 4",2014-08-19 13:20:00-04:00,OTIC,positive
968081.0,"Shares of Otonomy Have Opened at $18.13/Share, IPO Priced at $16",2014-08-13 10:32:00-04:00,OTIC,positive
968082.0,Waiting on 2 IPOs This Morning,2014-08-13 08:27:00-04:00,OTIC,neutral
968083.0,Otonomy Prices 6.25M Share IPO at $16/Share,2014-08-13 08:02:00-04:00,OTIC,positive
968084.0,IPOs This Week: Are Otonomy And C1 Financial Worth A Look?,2014-08-11 09:50:00-04:00,OTIC,positive
